UNITE glioblastoma

Understanding and targeting resistance in glioblastoma

We aim to develop concepts to predict and monitor treatment response and failure, and ultimately, to discover novel therapies for glioblastoma patients

More about UNITE
Link to: ResearchLink to: School

MEMBERS

UNITE Glioblastoma brings together physician-scientists and scientists from Heidelberg University Hospital, University Hospital Mannheim, the German Cancer Research Center and Mannheim University of Applied Sciences.

EVENTS

UNITE coordinates regular seminars and symposia with internal and external speakers presenting the latest research findings in glioblastoma research.

Participating Institutions

ArticleIL4I1 IS A METABOLIC IMMUNE CHECKPOINT THAT ACTIVATES THE AHR AND PROMOTES TUMOR PROGRESSION

  Research findings related to UNITE work package C04 Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor malignancy and suppresses anti-tumor immunity. The…
UNITE

HETEROGENEITY OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN HYPERMUTATED EXPERIMENTAL GLIOMAS

Research findings related to UNITE work package B01 Intrinsic malignant brain tumors, such as glioblastomas are frequently resistant to immune checkpoint blockade (ICB) with few hypermutated glioblastomas…

SUPERIORITY OF TEMOZOLOMIDE OVER RADIOTHERAPY FOR ELDERLY PATIENTS WITH RTK II METHYLATION CLASS, MGMT PROMOTER-METHYLATED MALIGNANT ASTROCYTOMA

Research findings related to clinical trial development within UNITE O6-methylguanine DNA-methyl transferase (MGMT) promoter methylation status is predictive for alkylating chemotherapy, but there are…